Igor Smolenov

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Venues

Nature communications

Human vaccines & immunotherapeutics

Seqirus (United States)

Volgograd State Medical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Seqirus (United States)

United States

TA Head :: Clinical Development

Education History

Volgograd State Medical University

Russia

PHD :: Clinical Pharmacology

Publications

Nhân Thị Hồ, Steven G Hughes, Van Thanh Ta, Lân Trọng Phan, Quyết Đỗ, Thượng Vũ Nguyễn, Anh Thị Văn Phạm, Mai Thị Ngọc Đặng, Lượng Viết Nguyễn, Quang Vinh Trịnh, Hùng Ngọc Phạm, Mến Văn Chử, Toàn Trọng Nguyễn, Quang Chấn Lương, Vy Thị Tường Lê, Thắng Văn Nguyễn, Lý-Thi-Lê Trần, Anh Thi Van Luu, Anh Ngoc Nguyen, Nhung-Thi-Hong Nguyen, Hai-Son Vu, Jonathan M Edelman, Suezanne Parker, Brian B Sullivan, Sean Sullivan, Qian Ruan, Brenda Clemente, Brian Luk, Kelly Lindert, Dina Berdieva, Kat Murphy, Rose Sekulovich, Benjamin Greener, Igor Smolenov, Pad Chivukula, Vân Thu Nguyễn, Xuan-Hung Nguyen
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nature communications 15 (1) (2024)
Nhân Thị Hồ, Steven G Hughes, Van Thanh Ta, Lân Trọng Phan, Quyết Đỗ, Thượng Vũ Nguyễn, Anh Thị Văn Phạm, Mai Thị Ngọc Đặng, Lượng Viết Nguyễn, Quang Vinh Trịnh, Hùng Ngọc Phạm, Mến Văn Chử, Toàn Trọng Nguyễn, Quang Chấn Lương, Vy Thị Tường Lê, Thắng Văn Nguyễn, Lý-Thi-Lê Trần, Anh Thi Van Luu, Anh Ngoc Nguyen, Nhung-Thi-Hong Nguyen, Hai-Son Vu, Jonathan M Edelman, Suezanne Parker, Brian B Sullivan, Sean Sullivan, Qian Ruan, Brenda Clemente, Brian Luk, Kelly Lindert, Dina Berdieva, Kat Murphy, Rose Sekulovich, Benjamin Greener, Igor Smolenov, Pad Chivukula, Vân Thu Nguyễn, Xuan-Hung Nguyen
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nature communications 15 (1) (2024)
Nhân Thị Hồ, Steven G Hughes, Van Thanh Ta, Lân Trọng Phan, Quyết Đỗ, Thượng Vũ Nguyễn, Anh Thị Văn Phạm, Mai Thị Ngọc Đặng, Lượng Viết Nguyễn, Quang Vinh Trịnh, Hùng Ngọc Phạm, Mến Văn Chử, Toàn Trọng Nguyễn, Quang Chấn Lương, Vy Thị Tường Lê, Thắng Văn Nguyễn, Lý-Thi-Lê Trần, Anh Thi Van Luu, Anh Ngoc Nguyen, Nhung-Thi-Hong Nguyen, Hai-Son Vu, Jonathan M Edelman, Suezanne Parker, Brian B Sullivan, Sean Sullivan, Qian Ruan, Brenda Clemente, Brian Luk, Kelly Lindert, Dina Berdieva, Kat Murphy, Rose Sekulovich, Benjamin Greener, Igor Smolenov, Pad Chivukula, Vân Thu Nguyễn, Xuan-Hung Nguyen
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nature communications 15 (1) (2024)
Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, Camilo A Rodriguez, Josefina Carlos, May Emmeline B Montellano, Edison R Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents. Human vaccines & immunotherapeutics (2023)
Antonios O Aliprantis, Christine A Shaw, Paul Griffin, Nicholas Farinola, Radha A Railkar, Xin Cao, Wen Liu, Jeffrey R Sachs, Christine J Swenson, Heather Lee, Kara S Cox, Daniel S Spellman, Colleen J Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S Espeseth, Lori Panther
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human vaccines & immunotherapeutics 17 (5) (2020)

Igor Smolenov.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Igor Smolenov